Literature DB >> 33150778

Treatment Preferences of Patients with Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups in the United Kingdom, United States, and Germany.

Melanie Schroeder1, Katie Hall2, Lina Eliasson2, Sophia Bracey3, Necdet B Gunsoy4, Jake Macey3, Paul W Jones5, Afisi S Ismaila6,7.   

Abstract

BACKGROUND: A wide range of therapeutic regimens, including single-inhaler triple therapies (SITTs), are now available for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Thus, an improved understanding of patient preferences may be valuable to inform physician prescribing decisions. This study was performed to assess the factors considered by patients when making decisions about their COPD treatments using qualitative techniques.
METHODS: In the United Kingdom, United States and Germany, individual qualitative interviews (n=10 per country) and focus groups (1 per country; [United Kingdom, n=4; United States, n=6; Germany, n=6 participants]) were conducted. Interviews and focus groups were semi‑structured, lasting approximately 60 minutes, and focused on treatment preferences. Data were analyzed according to emerging themes identified from the interviews; qualitative thematic analysis of the data was performed using specialist software.
RESULTS: In interviews and focus groups, efficacy, ease of use, and lower frequency of use were favored attributes for current treatment, while side effects, medication taste, and more complex administration techniques were key dislikes. In interviews, most participants would consider a switch in medication, mainly for improved efficacy, but also to reduce medication frequency or following physician advice. Overall, efficacy and ease of use were the 2 most important attributes reported in interviews in all 3 countries.
CONCLUSION: Patients with COPD have preferences for certain attributes of medication, highlighting the multi-faceted nature of treatment effectiveness and the importance of the delivery device.These results were subsequently used to inform the design of a discrete choice experiment. JCOPDF
© 2020.

Entities:  

Keywords:  chronic obstructive pulmonary disease (COPD); discrete choice experiment (DCE); focus group; interview; multi-country; qualitative research; treatment preferences

Year:  2021        PMID: 33150778      PMCID: PMC8047617          DOI: 10.15326/jcopdf.8.1.2020.0131

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  28 in total

Review 1.  Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research.

Authors:  Cicely Kerr; Annabel Nixon; Diane Wild
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2010-06       Impact factor: 2.217

2.  Factors associated with medication nonadherence in patients with COPD.

Authors:  Johnson George; David C M Kong; Rambha Thoman; Kay Stewart
Journal:  Chest       Date:  2005-11       Impact factor: 9.410

3.  Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.

Authors:  Andrew P Yu; Annie Guérin; Diego Ponce de Leon; Karthik Ramakrishnan; Eric Q Wu; Michelle Mocarski; Steve Blum; Juliana Setyawan
Journal:  J Med Econ       Date:  2011-06-16       Impact factor: 2.448

4.  COPD-treating nurses' preferences for inhaler attributes - a discrete choice experiment.

Authors:  Mette Bøgelund; Lise Hagelund; Mikael Bergholdt Asmussen
Journal:  Curr Med Res Opin       Date:  2016-10-10       Impact factor: 2.580

5.  Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Authors:  David A Lipson; Frank Barnhart; Noushin Brealey; Jean Brooks; Gerard J Criner; Nicola C Day; Mark T Dransfield; David M G Halpin; MeiLan K Han; C Elaine Jones; Sally Kilbride; Peter Lange; David A Lomas; Fernando J Martinez; Dave Singh; Maggie Tabberer; Robert A Wise; Steven J Pascoe
Journal:  N Engl J Med       Date:  2018-04-18       Impact factor: 91.245

6.  FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.

Authors:  David A Lipson; Helen Barnacle; Ruby Birk; Noushin Brealey; Nicholas Locantore; David A Lomas; Andrea Ludwig-Sengpiel; Rajat Mohindra; Maggie Tabberer; Chang-Qing Zhu; Steven J Pascoe
Journal:  Am J Respir Crit Care Med       Date:  2017-08-15       Impact factor: 21.405

7.  Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

Authors:  D Singh; J Brooks; G Hagan; A Cahn; B J O'Connor
Journal:  Thorax       Date:  2008-02-01       Impact factor: 9.139

8.  Relationships between repeated instruction on inhalation therapy, medication adherence, and health status in chronic obstructive pulmonary disease.

Authors:  Masaya Takemura; Katsumi Mitsui; Ryo Itotani; Manabu Ishitoko; Shinko Suzuki; Masataka Matsumoto; Kensaku Aihara; Tsuyoshi Oguma; Tetsuya Ueda; Hitoshi Kagioka; Motonari Fukui
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-01-20

9.  Evaluation of patient preference and willingness to pay for attributes of maintenance medication for chronic obstructive pulmonary disease (COPD).

Authors:  Ariane K Kawata; Leah Kleinman; Gale Harding; Sulabha Ramachandran
Journal:  Patient       Date:  2014       Impact factor: 3.883

10.  Health behaviors and their correlates among participants in the Continuing to Confront COPD International Patient Survey.

Authors:  Hana Müllerová; Sarah H Landis; Zaurbek Aisanov; Kourtney J Davis; Masakazu Ichinose; David M Mannino; Joe Maskell; Ana M Menezes; Thys van der Molen; Yeon-Mok Oh; Maggie Tabberer; MeiLan K Han
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-04-27
View more
  1 in total

Review 1.  Individual trajectory-based care for COPD: getting closer, but not there yet.

Authors:  Nicolas Roche; Philippe Devillier; Patrick Berger; Arnaud Bourdin; Daniel Dusser; Jean-François Muir; Yan Martinat; Philippe Terrioux; Bruno Housset
Journal:  ERJ Open Res       Date:  2021-12-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.